Wolverine peptides (BPC-157 + TB-500): chemistry, labels and UK status

Overview

The products named on this page are supplied for laboratory research only and are not for human or veterinary use. They are not licensed medicines, and none is authorised by the MHRA for any medical use. This guide covers each component, how the Wolverine 40mg pen compares with the BPC-157 + TB-500 bundle and the single pens, anti-doping and UK regulatory status, storage and documentation. It gives no use instructions.

Four products in this shop contain one or both of these peptides. Their labels describe them as follows.

Wolverine 40mg Pen (labelled WOLVERINE KLIK). One prefilled pen with both peptides in the same solution: 20 mg BPC-157 plus 20 mg TB-500, 40 mg in total. The label reads “BPC157+TB500 (20mg+20mg/3ml)”. Because the two peptides share one cartridge, any analysis has to identify and measure both in the same sample.

BPC-157 + TB-500 Pen Bundle. Two separate prefilled pens sold together: a KLIK157 pen labelled BPC-157 10 mg and a KLIK500 pen labelled TB-500 10 mg, each printed “10mg/2mL” and each holding one compound.

BPC-157 10mg Pen (KLIK157) and TB-500 10mg Pen (KLIK500). The same single-compound pens, sold individually.

Put simply, the Wolverine pen holds twice the labelled amount of each peptide found in the bundle, combined in one pen. The bundle and the single pens keep the two compounds apart.

Sport. Both components are prohibited at all times, in and out of competition, on the World Anti-Doping Agency (WADA) Prohibited List. The 2026 List names BPC-157 in class S0 (substances with no current approval for therapeutic use) and lists “thymosin-β4 and its derivatives e.g. TB-500” in S2.3 (growth factors and growth factor modulators). The 2027 List, published on 21 September 2026 and in force from 1 January 2027, keeps BPC-157 under S0 and TB-500 under S2, according to the US Anti-Doping Agency. UK Anti-Doping (UKAD) notes clearer S0 wording on peptides under clinical development.

UK regulation. Neither peptide is a licensed medicine in the UK. The US Food and Drug Administration's July 2026 reviews found no approved BPC-157 product in any country. For TB-500 they found no approved product in the UK or in the nine other countries checked, and the European Medicines Agency has not authorised one. Under the Human Medicines Regulations 2012 the MHRA decides case by case whether a product is a medicinal product, looking at its function and its presentation, including labelling, packaging, websites, social media and customer reviews. Selling, supplying or advertising a medicinal product without authorisation is an offence.

A statement that a product is not a medicine, or is for research use only, does not settle the question: the MHRA looks at the product as a whole, including its form, packaging and how it is presented. EU case law summarised in MHRA Guidance Note 8 (Delattre, C-369/88) holds that a statement that a product is not medicinal is persuasive evidence but not conclusive, and that a product can be regarded as presented as a medicine if its form and packaging make it sufficiently similar to one. This is a summary, not legal advice.

Documentation. A certificate of analysis for the Wolverine pen has to identify and quantify each peptide in that pen, matched to the batch on the label. A report for a single BPC-157 or TB-500 pen does not carry over to the combined pen, or the other way round. On 22 October 2026 the shop's certificates page listed no matching report for the Wolverine 40mg pen, the bundle or the 10mg BPC-157 and TB-500 pens.

Commercial note. This shop sells the products described here, and the product link on this page is commercial. No published research on BPC-157 or TB-500 tested this shop's stock.

Discovery & Background

BPC-157 was first synthesised at the University of Zagreb, Croatia, in the early 1990s. It was described in 1993 as a 15-residue fragment of “body protection compound” (BPC), a larger protein isolated from human gastric juice, and has also been known by the development code PL 14736 and the name Bepecin. TB-500 is a common name, not an official drug name: the FDA notes that it is not a United States Adopted Name. In 2012 the doping-control laboratory at Ghent University identified the N-acetylated 17–23 fragment of thymosin beta-4 (Ac-LKKTETQ) in a product called TB-500, synthesised it, and proposed a method for detecting it in plasma and urine. Selling the two peptides together as “Wolverine” is a retail convention rather than a laboratory one. The name carries no chemical meaning, and nothing standardises what a product sold under it contains, so the label and the certificate of analysis are what identify it.

Mechanism of Action

This section describes what the blend is chemically. It makes no claim about effects. The Wolverine blend is two unrelated synthetic peptides in one solution. Both names are common names rather than official nonproprietary names, neither compound has a monograph in the US, European or Japanese pharmacopoeias, and the FDA reports that different salts, and sometimes different molecules, are sold under both names. The sequence and molecular weight on a certificate of analysis therefore matter more than the name on the box.

• 1
  BPC-157 is a linear 15-residue peptide: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). The free base is C62H98N16O22, molecular weight 1419.5 g/mol, CAS 137525-51-0. The acetate salt has its own CAS number, 216441-37-1. It is produced synthetically (the FDA describes solid-phase peptide synthesis), not extracted.
• 2
  TB-500 is an N-acetylated 7-residue peptide: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ). The free base is C38H68N10O14, 889.0 g/mol, CAS 885340-08-9; the acetate salt is about 949.1 g/mol. The FDA notes that some suppliers quote the free-base CAS number for the acetate.
• 3
  TB-500's sequence matches residues 17–23 of thymosin beta-4, a 43-residue protein. UniProt record P62328 lists 44 encoded residues and notes that the first methionine is removed, so in the record's own numbering the same sequence sits at positions 18–24. TB-500 is a fragment, not thymosin beta-4 itself, although “TB-500” and “TB4” are sometimes used loosely for the whole protein.
• 4
  Equal labelled masses are not equal molar amounts. TB-500 is the smaller molecule, so 20 mg of TB-500 free base contains roughly 1.6 times as many molecules as 20 mg of BPC-157 free base. Salt forms shift these figures.
• 5
  Identity testing: the Ghent laboratory identified TB-500 by liquid chromatography with high-resolution mass spectrometry. BPC-157 and TB-500 differ widely in molecular weight (about 1419 and 889 g/mol), so mass spectrometry can in principle tell them apart in a single sample.

Frequently Asked Questions